Kidney Fibrosis – Pipeline Review, H2 2012

Kidney Fibrosis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Kidney Fibrosis - Pipeline Review, H2 2012', provides an overview of the Kidney Fibrosis therapeutic pipeline. This report provides information on the therapeutic development for Kidney Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Fibrosis. 'Kidney Fibrosis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Kidney Fibrosis.
- A review of the Kidney Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Kidney Fibrosis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Kidney Fibrosis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Kidney Fibrosis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Kidney Fibrosis 7
Kidney Fibrosis Therapeutics under Development by Companies 9
Early Clinical Stage Products 10
Comparative Analysis 10
Discovery and Pre-Clinical Stage Products 11
Comparative Analysis 11
Kidney Fibrosis Therapeutics – Products under Development by Companies 12
Companies Involved in Kidney Fibrosis Therapeutics Development 13
Bristol-Myers Squibb Company 13
BioLineRx, Ltd. 14
Paloma Pharmaceuticals, Inc. 15
Angion Biomedica Corp. 16
Thrasos, Inc. 17
Kidney Fibrosis – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
CGEN-856 - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
THR-123 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Palomid 529 Oral - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
AM-095 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
F351 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ANG-3298 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Kidney Fibrosis Therapeutics – Drug Profile Updates 31
Kidney Fibrosis – Product Development Milestones 32
Featured News & Press Releases 32
Oct 20, 2010: GNI Receives F351 Patent Allowance in Japan 32
Aug 26, 2010: GNI Receives F351 Patent Allowance in Canada 32
Nov 07, 2007: China Patent and Trademark Office Grants Patent for F351, GNI’s Key Therapeutic Product for Liver Disease 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34

List of Tables
Number of Products Under Development for Kidney Fibrosis, H2 2012 7
Products under Development for Kidney Fibrosis – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Early Clinical Stage Development, H2 2012 10
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 11
Products under Development by Companies, H2 2012 12
Bristol-Myers Squibb Company, H2 2012 13
BioLineRx, Ltd., H2 2012 14
Paloma Pharmaceuticals, Inc., H2 2012 15
Angion Biomedica Corp., H2 2012 16
Thrasos, Inc., H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 22
Kidney Fibrosis Therapeutics – Drug Profile Updates 31

List of Figures
Number of Products under Development for Kidney Fibrosis, H2 2012 7
Products under Development for Kidney Fibrosis – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Early Clinical Stage Products, H2 2012 10
Discovery and Pre-Clinical Stage Products, H2 2012 11
Assessment by Monotherapy Products, H2 2012 18
Assessment by Route of Administration, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Molecule Type, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 22